SCYNEXIS, Inc. Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon
11/7/2011 11:23:38 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today presented data demonstrating that SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection—reactivates the body’s natural defense mechanism, making it capable of inhibiting replication of the virus. The data positions SCY-635 as a potential replacement for recombinant interferon—a component of the standard of care for hepatitis C treatment that is associated with significant side effects. The data were presented in a poster session at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. SCY-635 is currently undergoing Phase 2 studies.
comments powered by